Rigel PharmaceuticalsRIGL
RIGL
About: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Employees: 147
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]
98% more capital invested
Capital invested by funds: $97.3M [Q2] → $193M (+$95.8M) [Q3]
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
2% more funds holding
Funds holding: 90 [Q2] → 92 (+2) [Q3]
0.4% more ownership
Funds ownership: 67.39% [Q2] → 67.8% (+0.4%) [Q3]
61% less call options, than puts
Call options by funds: $2.83M | Put options by funds: $7.22M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
1%
downside
Avg. target
$35
73%
upside
High target
$57
183%
upside
5 analyst ratings
2 positive
40%
3 neutral
60%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 29% 1-year accuracy 117 / 398 met price target | 183%upside $57 | Buy Reiterated | 14 Jan 2025 |
Cantor Fitzgerald Kristen Kluska 33% 1-year accuracy 35 / 107 met price target | 24%upside $25 | Neutral Maintained | 10 Dec 2024 |
B. Riley Securities Kalpit Patel 11% 1-year accuracy 1 / 9 met price target | 1%downside $20 | Neutral Maintained | 10 Dec 2024 |
Piper Sandler Allison Bratzel 80% 1-year accuracy 8 / 10 met price target | 14%upside $23 | Neutral Maintained | 14 Nov 2024 |
Citigroup Yigal Nochomovitz 24% 1-year accuracy 11 / 45 met price target | 143%upside $49 | Buy Maintained | 12 Nov 2024 |
Financial journalist opinion
Based on 11 articles about RIGL published over the past 30 days
Positive
Zacks Investment Research
3 days ago
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 75.8% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
3 days ago
Best Momentum Stock to Buy for January 17th
WFC, FHN and RIGL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 17, 2025.
Positive
Zacks Investment Research
3 days ago
New Strong Buy Stocks for January 17th
RIGL, PFIS, PBPB, ICL and KMX have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2025.
Positive
Zacks Investment Research
5 days ago
Rigel (RIGL) Upgraded to Buy: Here's Why
Rigel (RIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
PRNewsWire
1 week ago
Rigel Provides Business Update and 2025 Outlook
Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million R289 granted Orphan Drug designation by the FDA for the treatment of MDS Rigel anticipates 2025 total revenue of approximately $200 to $210 million SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today provided a business update including preliminary total revenue and net product sales for the fourth quarter of 2024, ongoing activity from the commercial business and development pipeline, and its financial outlook for 2025.
Positive
Zacks Investment Research
1 week ago
Small-Cap Stocks Can Outperform Large-Cap Peers in 2025: 5 Top Picks
We have picked five small-cap stocks that have strong growth potential for 2025. These are: TZOO, EVER, LIND, RIGL, GHM.
Neutral
PRNewsWire
1 week ago
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
SOUTH SAN FRANCISCO, Calif. , Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS).
Neutral
PRNewsWire
1 week ago
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P.
Neutral
PRNewsWire
2 weeks ago
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
Positive
Seeking Alpha
3 weeks ago
Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents
Rigel Pharmaceuticals has shown significant growth, particularly from the acquisition of pralsetinib, leading to a 46% improvement in stock valuation since April. Rigel's pipeline includes three approved drugs and promising candidates like R289 and ocadusertib, with notable advancements in clinical trials and Fast Track designation. Financially, RIGL has turned profitable with a $12.4 million net income in the latest quarter, but high debt and potential cash flow challenges loom.
Charts implemented using Lightweight Charts™